SCHEMBL5468375

SCHEMBL5468375

O=C1S/C(=C\c2ccc(O)c(O)c2)C(=O)N1Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
MAPK1 P28482 4/20 0.67
POLB P06746 3/20 0.67
ALDH1A1 P00352 3/20 0.67
MAPT P10636 3/20 0.67
TDP1 Q9NUW8 2/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
CRHBP P24387 1/20 0.67
CRHR2 Q13324 1/20 0.67
NOD2 Q9HC29 1/20 0.67
AKR1B1 P15121 1/20 0.59
ENPP2 Q13822 2/20 0.59
AMY1A P0DUB6 1/20 0.58
HSP90AA1 P07900 1/20 0.57
GAA P10253 1/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5468379 1.00 MEN1 (0.67) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL5469841 0.89 MAPK1 (0.62) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL5469842 0.89 MAPK1 (0.62) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL5470014 0.89 MAPK1 (0.85) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL5470020 0.89 MAPK1 (0.85) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL15682751 0.84 MEN1 (0.61) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL15682752 0.84 MEN1 (0.78) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL6692200 0.83 PPARG (0.68) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL6692202 0.83 PPARG (0.68) MEN1KMT2AMAPK1POLBALDH1A1
SCHEMBL5455135 0.82 MAPK1 (0.59) MEN1KMT2AMAPK1POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MEN1 2892/4885KMT2A 2948/4885MAPK1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.